Protocol  I6T-MC-AMBV (a)  
 
Relative Bioavailability of a Mirikizumab Test Formulation  Compared to the Reference 
Formulation in  Healthy Subjects  
 
[STUDY_ID_REMOVED] 
 Approval Date: 17- Aug-2020 
 
 
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 1
LY3074828Protocol I6T-MC-AMBV(a)
Relative Bioavailability  of a Mirikizumab Test Formulat ion 
Compared to the Reference Formulation in 
Healthy Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
mirikizumab (LY3074828) , unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercia lly confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Mirikizumab ( LY3074828 )
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly on 
13December 2019 
Protocol amendment (a) Electronically Signed and Approved by Lilly on date provided 
below.
Approval Date: 17-Aug-2020 GMT
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 2
LY3074828Table of Contents
Relative Bioavailability  of aMirikizumab Test Formulation 
Compared to the Reference Formulation in Healthy Subjects
Section Page
Protocol  I6T-MC-AMBV (a) Relat ive Bioavailabilit y of a Mi rikizumab 
Test F ormulation Compared to the Reference Formulat ion in 
HealthySubjects ................................ ................................ ................................ ................. 1
Table of Contents ................................ ................................ ................................ ........................ 2
1. Protocol  Synopsi s................................ ................................ ................................ ................ 7
2. Schedule of Act ivities................................ ................................ ................................ ......... 9
3. Introduction ................................ ................................ ................................ ...................... 14
3.1. Study  Rati onale ................................ ................................ ................................ ............ 14
3.2. Backgro und................................ ................................ ................................ .................. 14
3.2.1. Deaths, Serious Adverse Events, and Discont inuations due to 
an Adverse Event ................................ ................................ ................................ .15
3.2.2. Other Treatment -Emergent Adverse Events ................................ .......................... 15
3.2.3. Pharmacokinet ics................................ ................................ ................................ .16
3.2.4. Immunogenicit y................................ ................................ ................................ ...16
3.3. Benefit/Risk Assessment ................................ ................................ .............................. 16
4. Object ives and Endpo ints................................ ................................ ................................ ..17
5. Study  Design ................................ ................................ ................................ ..................... 18
5.1. Overall Design ................................ ................................ ................................ ............. 18
5.2. Number of Participants ................................ ................................ ................................ .18
5.3. End of Study  Definit ion................................ ................................ ............................... 18
5.4. Scientific Rationale for Study  Design ................................ ................................ ........... 19
5.5. Justification for Dose ................................ ................................ ................................ ...19
6. Study Populat ion................................ ................................ ................................ ............... 20
6.1. Inclusio n Cri teria................................ ................................ ................................ .......... 20
6.2. Exclusio n Cri teria................................ ................................ ................................ ........ 22
6.2.1. Rationale for Excl usion of Certain Study  Candidates ................................ ........... 24
6.3. Lifest yle and/or Dietary Requirements ................................ ................................ ......... 25
6.3.1. Meals and Dietary  Restri ctions................................ ................................ ............. 25
6.3.2. Caffeine, Alcoho l, and Tobacco ................................ ................................ ........... 25
6.3.3. Activity................................ ................................ ................................ ................ 25
6.4. Screen Failures ................................ ................................ ................................ ............. 25
7. Treatment ................................ ................................ ................................ .......................... 26
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 3
LY30748287.1. Treatment Administered ................................ ................................ ............................... 26
7.1.1. Packaging and Labeling ................................ ................................ ....................... 26
7.1.2. Medical Device ................................ ................................ ................................ ....27
7.2. Method of Treatment Assignment ................................ ................................ ................ 27
7.2.1. Selection and Timing o f Doses ................................ ................................ ............. 27
7.3. Blinding ................................ ................................ ................................ ....................... 27
7.4. Dose Modificat ion................................ ................................ ................................ ........ 27
7.4.1. Speci al Treatm ent Consi derat ions................................ ................................ ........ 27
7.5. Preparati on/Handling/Storage/Accountabilit y................................ ............................... 28
7.6. Treatment Compliance ................................ ................................ ................................ .28
7.7. Concomitant Therapy ................................ ................................ ................................ ...28
7.8. Treatment after the End of the Study ................................ ................................ ............ 29
8. Discontinuati on Cri teria ................................ ................................ ................................ ....30
8.1. Discontinuati on from Study  Treatm ent................................ ................................ ......... 30
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects ................................ .............. 30
8.2. Discontinuati on from the Study ................................ ................................ .................... 30
8.3. Subjects Lost to Follow -up................................ ................................ ........................... 30
9. Study  Assessments and Procedures ................................ ................................ ................... 31
9.1. Efficacy Assessments ................................ ................................ ................................ ...31
9.2. Adverse Events ................................ ................................ ................................ ............ 31
9.2.1. Serious Adverse Events ................................ ................................ ........................ 32
9.2.1.1. Adverse Device Effects ................................ ................................ .................. 32
9.2.1.2. Adverse Events of Special Interest ................................ ................................ ..33
9.2.1.3. Suspected Unexpected Serious Adverse React ions................................ .......... 33
9.2.2. Com plaint Handling ................................ ................................ ............................. 33
9.3. Treatment of Overdose ................................ ................................ ................................ .34
9.4. Safety................................ ................................ ................................ ........................... 34
9.4.1. Laboratory  Tests ................................ ................................ ................................ ..34
9.4.2. Vital Signs................................ ................................ ................................ ........... 34
9.4.3. Electrocardiograms ................................ ................................ .............................. 34
9.4.4. Temperature ................................ ................................ ................................ ......... 34
9.4.5. Other T ests................................ ................................ ................................ ........... 35
9.4.5.1. Tuberculosis Test ing................................ ................................ ....................... 35
9.4.5.2. Inject ion-Site Bl eeding ................................ ................................ ................... 35
9.4.5.3. Inject ion-Site Assessments ................................ ................................ ............. 35
9.4.5.3.1. Inject ion-Site Pain ................................ ................................ .................... 35
9.4.6. Safety Moni toring ................................ ................................ ................................ 36
9.4.6.1. Hepati c Safet y................................ ................................ ................................ 36
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 4
LY30748289.5. Pharm acokinet ics................................ ................................ ................................ ......... 36
9.5.1. Bioanalysis ................................ ................................ ................................ ........... 37
9.6. Pharmacodynamics ................................ ................................ ................................ ......37
9.6.1. Immunogenicit y Assessments ................................ ................................ .............. 37
9.7. Genet ics................................ ................................ ................................ ....................... 37
9.8. Biomarkers ................................ ................................ ................................ ................... 38
9.9. Health Economics ................................ ................................ ................................ ........ 38
10. Statistical Considerations and Data Analysis ................................ ................................ .....39
10.1. Sample Si ze Determinat ion................................ ................................ .......................... 39
10.2. Popul ations for Analyses ................................ ................................ .............................. 39
10.2.1. Study  Parti cipant Disposit ion................................ ................................ ............... 39
10.2.2. Study  Parti cipant Characterist ics................................ ................................ .......... 39
10.3. Statistical Analyses ................................ ................................ ................................ ......39
10.3.1. Safety Analyses ................................ ................................ ................................ ....39
10.3.1.1. Clinical Evaluation of Safet y................................ ................................ .......... 39
10.3.1.2. Statistical Evaluat ion of Safet y................................ ................................ ....... 40
10.3.1.2.1. Inject ion-Site Pain ................................ ................................ .................... 40
10.3.1.2.2. Statistical Evaluat ion of Other Safet y Param eters ................................ ......40
10.3.2. Pharmacokinet ic Analyses ................................ ................................ .................... 40
10.3.2.1. Pharmacokinet ic Parameter Estimat ion................................ ........................... 40
10.3.2.2. Pharmacokinet ic Statistical Inference ................................ ............................. 40
10.3.3. Evaluat ion of Immunogenicit y................................ ................................ ............. 41
10.3.4. Data Review during the Study ................................ ................................ .............. 41
10.3.5. Interim Analyses ................................ ................................ ................................ ..41
11. References ................................ ................................ ................................ ........................ 42
12. Appendices ................................ ................................ ................................ ....................... 43
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 5
LY3074828List of Tables
Table Page
Table AMBV.1. Object ives and Endpo ints................................ ................................ ....... 17
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 6
LY3074828List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................ ................................ 44
Appendix 2. Clinical Laboratory  Tests ................................ ................................ ........ 48
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 49
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 52
Appendix 5. Blood Sam pling Summary ................................ ................................ ......53
Appendix 6. Allergic/Hypersensit ivity Reaction Kit ................................ ................... 54
Appendix 7. Protocol  Amendment I6T -MC-AMBV (a) Summary  Relat ive 
Bioavailabilit y of a Mirikizumab Test Formulat ion Com pared to 
the Reference Formulat ion in HealthySubjects ................................ ....... 55
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 7
LY30748281.Protocol Synopsis
Title of Study:
Relativ e Bioavailability of a Mirikizumab Test Formulation Compared to the Reference Formulation in 
Healthy Subjects
Rationale: 
Changes in buffer composition are being investigated as a potential way to address injection -site reactions, including 
pain,for mirikizumab .  Study I6T -MC-AMBV (AMBV) is being conducted to evaluate the relative bioav ailabili ty 
and tolerability of mirikizumab administered using anew formulation compared to the reference formulatio nthat
has been administered in completed and ongoing clinical studies .
Objectives/Endpoints:
Objectives                 Endpoints
Primary
To evaluate the relative bioavailability of a single 200 -mg 
SC dose (2 ×1-mL PFS injections) of Mirikizumab 
Test Formulation compared to the Reference FormulationCmax, AUC(0 -∞), and AUC(0 -
tlast)
Secondary
To evaluate the safety and tolerability of a sing le 200 -mg 
SC dose (2 ×1-mL PFS injections) of Mirikizumab 
Test Formulation compared to the Reference FormulationTEAEs and SAEs
Abbreviations: AUC(0 -∞) = area under the concentration versus time curve from time zero to infinity; 
AUC(0 -tlast)= area under the concentration versus time curve from time zero to time t, w here t is the last time 
point with a measurable concentration; C max = maximum observed drug concentration; PFS = pre -filled syringe; 
SAE = serious adverse event; SC =subcutaneous; TEAE =treatmen t-emergent adverse event .
Summary of Study Design :
Study AMBV is a Phase 1, subject -blind, investigator -blind, 2-arm, randomized, single -dose, parallel -design study 
in healthy  subjects.
Eligible subjects will be admitted to the clinical research unit(CRU) on Day -1 and randomized 1:1 to 1 of 
2possible treatments and, within treatments ,1:1:1 to 3 possible injection locations (arm s, thigh s, or abdomen) using 
a computer -generated allocation code .  Subjects may be allowed to leave the CRU after com pleting the 4 -hour safety 
assessments on Day 1, at the investigator’s discretion, and will return for pharmacokinetic and immunogenicity 
sampling and safety assessments at predefined outpatient visits up to 12 weeks postdose.   Subjects will also be 
monitored for safety by way  of telephone assessment on 3 occasions when outpatient visits are separated by 
2weeks .  
Safety and tolerability will be assessed from clinical laboratory tests, vital sign measurements, recording of adverse 
events, physical ex aminatio n, and immunogenicity.  
Treatment Arms and Planned Duration for an Individual Subject :
All subjects will be screened within 28 days prior to enrollment .
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 8
LY3074828On Day  1, subjects will receive a single dose consisting of 2 subcutaneous injections of 1 of the following treatment
formulation s according to the randomization schedule:
200-mg Mirikizumab Reference Formulation (100mg/mL ), 2×1-mL pre-filled syringe (PFS)
(administered in complet ed and ongoing clinical studies )
200-mg Mirikizumab Test Formulation (100mg/mL ), 2×1-mL PFS
Subjects will participate in the study for up to 12 weeks postdose .
Number of Subjects:
Up to 60subjects may be enrolled to ensure the following number of subjects complete the study:
48 subjects randomized to 2 treatment formulations with approximately
o24 subjects per Reference and TestFormulations, respectively , and 
o8subjects per arms, thigh s, andabdomen injection location s, respectively, for each treatment 
formulation .
Statistical Analysis:
Pharmacokinetic parameters will be evaluated to estimate relative bioavailability of Test Formulation compared with 
the Reference Formulation .  Log -transformed maximum observed drug concentration (Cmax) and area under the 
concentration versus time curve (AUC)parameters will be evaluated in a linear mixed -effects model with fixed 
effects for formulation and injection -site location and a random effect for subject.  The treatment differences will be 
back-transformed to present the ratios of geometric means and the corresponding 90% confidence interval .
The time of Cmax (tmax) will be analyzed using a Wilcoxon rank sum test.  Estimates of the median difference based 
on the observed medians, 90% C Is,and p -values from the Wilcoxon rank sum test will be calculated.
Safety parameters will be listed and summarized using standard descriptive statistics , where possible .  
The frequency and percentage of subjects with preexisting antidrug antibodies ( ADA s)and with treatment -emergent
ADAs that are positive (TE-ADA +)to mirikizumab will be tabulated.  Forthe TE -ADA+ subjects ,the distribution 
of maximum titers will be described.  The frequency of neutralizing antibodi es will also be tabulated in 
TE-ADA+ subjects.
Additional analysis will be performed if warranted upon review of the data.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 9
LY30748282.Schedule of A ctivities
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 10
LY3074828Study Schedule Protocol I6T-MC-AMBV
Screening Study Day Comments
Procedure-28 to -2 
days prior 
to Day 1-1135
±1d8
±1d11
±1d15
±2d22
±2d29
±2d36
±2d43
±2d50
±2d57
±3d64
±2d71
±3d85
±3dor 
ED
Informed consent X
Medical history and 
demographicsX
Review and confirm 
inclusion and 
exclusion criteriaX X
Subject admissio n to 
CRUX
Subject discharge 
from CRUXSubjects discharged after 
completing the 4 -hour safety 
assessments on Day 1, at the 
investigator’s discretion.
Outpatient visit XX X X X X X X X X X
Safety assessment 
(telepho ne call)X X X
Randomization XSubjects will be randomized 
1:1 to 1 of 2treatment
formulation s and 1:1:1 to 1 of 
3injection locations per 
treatment formulation .
Height, weight, and 
BMIX XOnly weight will be 
measured on Day 85or ED.
Body temperature X X XX X X X X X X X X X
Physical 
examination
X X XFull physical examination at 
screening orDay -1(not 
both) .  Symptom -directed 
examinations and 
assessments at other times, 
and as deemed necessary by 
the investigator.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 11
LY3074828Screening Study Day Comments
Procedure-28 to -2 
days prior 
to Day 1-1135
±1d8
±1d11
±1d15
±2d22
±2d29
±2d36
±2d43
±2d50
±2d57
±3d64
±2d71
±3d85
±3dor 
ED
Vital signs (pulse 
rate, blood pressure, 
and temperature) 
(sitting )(hours)
X XP, 
2to 
4X X XDay 1:  2 -to 4-hour 
assessment (excluding 
temperature) to be conducted 
at least 2 hours after second 
injection and prior to 
discharge at approximately 4 
hours postdose.  Time points 
may be added if warranted 
and agreed upon between 
Lilly  and the investigator.
Clinical laboratory  
testsX X X X XSeeAppendix 2 , Clinical 
Laborato ry Tests, for details.
SerologyXSeeAppendix 2 , Clinical 
Laborato ry Tests, for details.
QuantiFERON ®-TB 
Gold testX
Ethanol test and 
drug screenX XMay be repeated at the 
discretio n of the investigator.
FSH testXFemales only, if applicable .
SeeSection 6.1.
Pregnancy test
(females only, as 
applicable)X X XSerum pregnancy test will be 
performed at screening and 
Day -1.  Urine pregnancy 
testwill be performed at 
Day 85or ED.  See Section 
6.1Inclusion [1b].
Single 12 -lead ECG
(supine)X XSingle screening ECG but 
may be obtained at additional 
times ,when deemed
clinically necessary.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 12
LY3074828Screening Study Day Comments
Procedure-28 to -2 
days prior 
to Day 1-1 1 35
±1d8
±1d11
±1d15
±2d22
±2d29
±2d36
±2d43
±2d50
±2d57
±3d64
±2d71
±3d85
±3dor 
ED
Mirikizumab
administration (2 
injections per dose )
XSee Section 7.1. 
Subjects will fast (only water 
is allowed) from 1 hour 
before until 1 hour after 
dosing.   
Injections at Times0 and 20 
± 2 min.
 
1Assess within the first minute 
and then, if there is bleeding, 
at 1-min intervals following 
the injection until the 
bleeding stops.  See Section 
9.4.5.2 .
 
 
 
 
 1, 5, 
15, 
30, 
60, 
120, 
240Assess all injections as 
described in Section 9.4.5.3 .  
Time points on Day 1 after 
each injection are
within 1 min ,
5 min (±1.5 min)
15 and 30 min (each ±2 
min), and
60, 120, and 240 min 
(each ±5min). 
For VAS, see Section 
9.4.5.3.1.
Mirikizumab PK 
sampleP X X X X X X X X X X X
CCI
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 13
LY3074828Screening Study Day Comments
Procedure-28 to -2 
days prior 
to Day 1-1 1 35
±1d8
±1d11
±1d15
±2d22
±2d29
±2d36
±2d43
±2d50
±2d57
±3d64
±2d71
±3d85
±3dor 
ED
 P X X X
 X
AE and concomitant 
medication X X X X X X X X X X X X X X X X XISRs will be reported on 
supplemental ISR form, and 
not as AEs
Abbreviations: AE = adverse event; BMI = body mass index; CRU = clinical research unit; d =day; ECG = electrocardiogram; ED =early  discontinuation; 
FSH = follicle -stimulating hormone; ISR = injection -site reaction; min = minutes; P = pre -dose; PK =pharmacokinetic (s); SC=subcutaneous; TB = 
tuberculosis; VAS = visual analog scale.
aAdministration of the pain VAS is mandatory at 1, 5 ,and 15 min regardless of whether pain is reported as "y es" or "no" during the injection -site assessment . 
Atother time points, the VAS is adm inistered only if pain is reported as "yes" during aninjection -site assessment .
CCI
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 14
LY30748283.Introduction
3.1. Study Rationale
Mirikizumab (LY3074828) as a solut ion formulation is current ly being studied in Phase 3 trials 
for the treatm ent of  psori asis,ulcerat ive colit is(UC) ,and Crohn’s disease.   In Phase 3 UCtrials,
a 200-mg dose of mirikizumab (2× 1-mL inject ions)is being administered .  In a Phase 3 
Crohn’s disease trial ,a 300 -mg dose (1× 2-mL and 1 × 1- mL inject ions)is being administered .
Inject ion-site reacti ons(ISRs) , including pain, have been reported in these studies, which use the 
mirikizumab “reference ”formulation.  Several so lution-associ ated factors m ay contribute to pain 
percepti on associ ated wi th injectable therapeutics, including active pharmaceut ical ingredient, 
pH, buffer composit ion, and tonicit y (Laursen et al. 2006 ).  
To potentially lessen ISRs, including pain , Lilly  devel oped an al ternate (test)formulation of 
mirikizumab that uses a different combinat ion of buffer and tonicit y agents to that of the 
reference formulation.  The  
 which are 
commo nly used excipients in formulations of m onocl onal ant ibodies. The active ingredient 
concentration and the inject ion volume remain the same as the reference formulation.  The 
referenc e formulation contains the inact ive ingredients anhydrous citric acid, polysorbate 80, 
sodium chl oride, and sodi um citrate dihydrate.
Study  I6T-MC-AMBV (AMBV) will evaluate the relat ive bioavailabilit y and tol erabili ty of this 
test formulat ion compared to the reference formulation when administered subcutaneously  (SC) 
using a pre -filled syringe (PFS).  This is the first human administration o f the test formulat ion.
3.2. Background
Mirikizumab is a humanized immunoglobulin G4 ‒variant monoclonal ant ibody  that i s directed 
against the p19 subunit of interleukin (IL) -23 and does not bind IL -12.  Mi rikizumab is being 
developed for the treatment of autoimmune diseases , including UC,in which the IL -23 pathway  
is thought to have a significant pathogenic role.  Neutraliz ation of IL -23 wi th an ant i-mouse IL -
23 surrogate antibody  (directed against the p19 subunit) significant ly reduced the development of 
arthri tis and inhibited ileal inflammat ion in a mouse model of spondyloarthropathy  with bowel  
inflammat ion (Ruutu et al. 2012).  Addit ionally , neutralizat ion of IL -23 si gnificant ly reduced the 
disease score in the relapsing -remitt ing experimental autoimmune encephalo myelitis (mult iple 
sclerosi s-like) m odel in mice.  Anti -IL-23 ant ibody also demonstrated some efficacy in 
preclinical arthritis models, depending on the timing of intervent ion (Cornelissen et al. 2013) .  
Ulcerat ive co litis is a chronic disease of unknown etio logy characterized by inflammat ion of the 
rectum  and col on.  Symptom s include diarrhea, rectal bleeding, urgency, and tenesmus (a feeling 
of incomplete evacuat ion of the rectum after defecation).  Ulcerat ive co litishas a rel apsing –
remitting course, meaning that many pat ients have intermittent disease flares that are 
interspersed wi th periods of  remissi on.  Treatm ent goals in UC include induct ion of remissio n 
(typically  within a 6-to 12 -week time frame) and maintenance of remissio n in the longer term 
(assessed over 52 weeks of continuous treatment in c linical trials).  Con trol of intestinal 
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 15
LY3074828inflammat ion in UC is also associated with a reduction in the risk of hospitalizat ion, col ectomy ,
and in the lo nger term , UC -associ ated dysplasia and colorectal cancer.
As of the Invest igator’s Brochure (IB) cutoff date (06 Feb ruary 2019), there have been
approximately  1061 partici pants in studi es onmirikizumab.  These include 236 patients wi th 
psoriasis, 230 patients wi th UC, 186 patients wi th Crohn’s disease, and 409 healt hy subjects who 
were exposed to either placebo or mirikizumab at single doses ranging from 5 to 2400 mg.  
Across Phase 2 studies, mult iple doses of mirikizumab have been studied at a maximum of 
1000 mg intravenous (IV) and 300 mg SC .
Single IV doses of up to 600 mg mirikizumab were evaluated in Study I6T-MC-AMAA 
(AMAA; healt hy subjects and pat ients with psori asis) and up to 2400 mg in 
Study I6T-JE-AMAD (healt hy Caucasian and Japanese subjects) . No dose -related safet y or 
tolerabilit y issues were observed in these studies or in o ther ongoing clinical pharmaco logy 
studi es.  Subcutaneous bioavailabilit y was approximately 40% relative to IV administration in 
Study AMAA .  
In addit ion,3completed studi es (I6T-MC-AMAL [AMAL] , I6T-MC-AMAE [AMAE ], and I6T-
MC-AMAQ) and 1ongoi ng study  (I6T-MC-AMAR) compared the bioavailabilit y, safet y, and 
tolerabilit y of various formulat ions of mirikizumab.  These studies showed that mirikizumab was 
well tolerated ;however ,asymptomat ic reduct ions in neutrophil counts were seen in a minorit y of 
subjects .  The incidence of ISRs was highly  variable across studies and treatments, but ISRs
were mostlymild to m oderate pain and very slight to well -defined ery thema.
3.2.1. Deaths, Serious Adverse Events , and Discontinuations due to 
an Adverse Event
In Phase 1 studies with healt hy subjects or patients with psoriasis, n odeaths, serious adverse 
events (SAEs), or discont inuat ions due to an adverse event ( AE)were reported .  In Phase 2 and 3 
studi es wi thpatientshaving psori asis, UC, or Crohn's disease :
2 deaths occurred from myocardial  infarcti on and lung cancer, respectively, but neit her 
was considered related to study  drug , and
serious adverse events anddiscontinuations due to an AE sare summarized in the IB.
3.2.2. Other Treatment -Emergent Adverse Events
In Phase 1 studies, t he most frequently reported ( ≥5.0%) treatm ent-emergent adverse events 
(TEAEs )in the 442 healt hy subjects and patients with psoriasis treated wi th mirikizumab in 
clinical pharmaco logy studi es were ISRs (including injecti on-site pain), nasopharyngit is, and 
headache .Three of the clinical pharmaco logy studies (AABA, AMAL, and AMAE) actively  
observed inject ion sites to allow recording of ,eg, erythema, swelling, and induration.   
Treatment -emergent adverse event s in Phase 2 and 3 studies wit h pat ients having psoriasis, UC, 
or Crohn ’s disease are summarized in the IB.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 16
LY30748283.2.3. Pharmacokinetics
Phase 1 studies in healt hy subjects and patients with psoriasis found that sy stemic exposure of 
mirikizumab increases in proportion to dose, and that mirikizumab has a half -life 
ofapproximately  10 days and SC bioavailabilit y of 40%.
 
 
3.3. Benefit/Risk Assessment
As wi th other immuno modulatory  thera pies, mirikizum ab may increase the risk of developing an 
infect ion or may exacerbate an exist ing infect ion.  These may  include opportunist ic infect ions 
and react ivation of latent infections, such as tuberculosis (TB) and hepat itis B.  Therefore, 
subjects testing positive for hepatit is B/C, human immu nodeficiency virus (HIV), or TBat 
screening will not be permitted to participate in this study .  Immunom odulatory  therapi es may 
increase the risk of ma lignancies; however, due to the single dose of mirikizumab being 
administered in this study , it is not consi dered necessar y to monitor forsuch effects.
Immediate hy persensi tivity react ions (anaphylact ic reacti onandinfusio n-related hypersensit ivity 
reacti on) including urticaria, angioedema, and anaphylaxis, have rarely  been reported with the 
administration of mirikizumab.
No other clinically significant safet y or tol erabilit y concerns have been ident ified to date in 
patients or heal thy subjects exposed to mirikizumab at up to the highest doses given (single 
2400 -mg IV and SC doses).  Ofnote,the 2400 -mg SC dose of mirikizuma b was administered in 
conjunction with human recombinant hyaluronidase as an integral co mponent of the formulat ion.
Healthy subjects are not expected to derive any benefit from participating in studies in which 
mirikizumab is administered .
More informat ion about the known and expected benefits, risks, SAEs ,and reasonably 
anticipated AEs of mirikizumab isto be found in the IB.
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 17
LY30748284.Objectives and Endpoints
Table AMBV .1shows the objectives and endpo ints of the study .
Table AMBV .1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the relative bioavailability of a 
single 200-mg SC dose (2 × 1-mL PFS 
injections) of Mirikizumab Test Formulation 
compared to the Reference FormulationCmax, AUC(0 -∞), and AUC(0 -tlast)
Secondary
To evaluate the safety and tolerability of a 
single 200-mg SC dose (2 × 1-mL PFS 
injections) of Mirikizumab Test 
Formulation compared to the 
Reference FormulationTEAEs and SAEs
 
 
  
 
 
Abbreviations: AUC(0 -∞) = area under the concentration versus time curve from time zero to infinity; 
AUC(0 -tlast)= area under the concentration versus time curve from time zero to t ime t, w here t is the last 
time point with a measurable concentration; C max= maximum obs erved drug conc entration; PFS =pre-filled 
syringe; PK = pharmacokinetics; SAE = serious adverse event; SC=subcutaneous; 
TE-ADA =treatment -emergent antidrug antibod y; TEAE =treatment -emergent adverse eve nt; 
VAS =visual analog scale.
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 18
LY30748285.Study  Design
5.1. OverallDesign
Study  AMBV is a Phase 1, subject -blind, invest igator -blind, 2-arm, rando mized, single -dose,
parallel -design study  in healt hy subjects.
All subjects will be screened within 28 days prior to enrollment.  Eligible subjects will be 
admitted to t he clinical research unit (CRU) on Day -1 and randomized 
1:1 to 2treatm entformulationsand 
within each treatm entformulation,1:1:1 to 3 injectio n sites (arm, thigh, or abdomen)
using a co mputer -generated allocat ion code (Section 7.2).  On Day  1, subjects will receive a 2×
1-mL ( 200 mg mirikizumab) SC dose of 1 of the following treatments according to the 
rando mizat ion sche dule:  
200mg Mirikizumab Reference Formulat ion(100mg/mL ), 2×1-mL PFS
(administered in co mpleted and ongoing clinical studi es [see Secti on3.2])
200mg Mirikizumab Test Formulat ion (100mg/mL), 2×1-mL PFS
The m aximum  total  dose of mi rikizumab a subject will receive is 200mg.
Subjects m ay be all owed to l eave the CRU after complet ingthe 4-hour safet y assessments on 
Day 1, at the invest igator’s discret ion, and will return for pharmacokinet ic (PK) and 
immunogenicit y sampling and safet y assessments at predefined t imes up to 12 weeks postdose.   
Subjects will be mo nitored for safet y betwe en outpatient visits by way o f telephone assessment .  
Subjects will part icipate in the study  for up to 12 weeks after lastdose.
Safety and tol erabilit y will  be assessed through clinical laboratory  tests, vi tal sign measurements, 
recording of AEs, physical examination, and immunogenicit y.  At prospectively defined time 
points, i nject ion-related assessments will be made including a pain visual analog scale (VAS) . 
Study  governance considerations are described in detail in Appendix 3 .
5.2. Number of Participants
Up to 60subjects may be enro lled so that 48subjects (24 subjects per formulat ionwith 
approximately  8 subjects per treatment formulat ion and inject ion site ) complete the study .  For 
the purposes of this study , a subject com pletes the study  when all  procedures shown in the 
Schedule of Act ivities (Section 2) have been co mpleted.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule 
ofActivities(Secti on 2) for the l ast subject.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 19
LY30748285.4. Scientific Rationale for Study Design
Conducting the study  in healt hy subjects mit igates the potenti al confounding effects of the 
disease state and concomitant medications in pat ients.  A populat ion of healt hy subjects is 
frequently used in the assessment of the relat ive bioavailabilit y of both sm all and 
large molecules.
Single doses of mirikizumab and the PK sampling time points ha ve been selected to generate 
PKprofiles sufficient to fulfill the study  objectives.
Subjects will be rando mized to receive injections in the arm s, thighs,or abdomen, as inject ion 
location hasbeen observed to have an impact on bioavailabilit y in so me studie s 
withmirikizumab.
A parallel -group desi gn was chosen because a crossover design is impract ical for mirikizumab , 
which has a half -life o f approximately  10.5 days.  Addit ionally , a crossover study  coul d 
confound PK d ata if subjects develop neutralizing ant idrug ant ibodies (ADAs) .  
5.5. Justification for Dose
The 200-mg dose of mirikizumab chosen for this study  isbased on 
200 m g being found safe and tolerable in Phase 2 studies
200 m g being evaluated in the Phase 3 UC development program , and
the volume o f solution that can be delivered through 2PFS (1mLper PFS) and the 
solubility of mirikizumab (100 mg/mL).
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 20
LY30748286.Study  Population
Eligibilit y of subjects for the study  will be based on the results of screening medical history , 
physical examinat ion, vital signs, clinical laboratory tests ,and electrocardiogram (ECG) at 
screening .
The nature of any condit ions present at the time of the physical examinat ionand any preexist ing 
condi tions will  be docum ented.  Laboratory  testsat screening and Day -1 may be repeated once 
at the discretion of the invest igator for any resul ts that are outside the reference range.
Screening may occur up to 28 day s prior to enrollment.  Subj ects who are not enrolled within 
28days of screening ma y be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, isnot permitted .
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening:
[1] are overtly healt hy male or female subjects, as determined through medical 
histor y and physical examinat ion
[1a] male subjects:
no male contraception required ,except in co mpliance wit h specific local 
government study  requi rement s
[1b] female subjects:
All female subjects must test negative for pregnancy  prior to ini tiation of 
treatm ent,as indicated by negat ive serum pregna ncy test at the screening visit and
on Day  -1prior to initial exposure to mi rikizumab
Women of childbearing potential who are abstinent (if this is co mplete abst inence ,
as thei r pref erred and usual lifest yle) or in a same -sex rel ationship (as part of their 
preferred and usual lifest yle) must agree to either remain abst inent or stay in a 
same -sex rel ationship wi thout sexual relat ionships with males.  Periodic 
abstinence ( eg, calendar, ovulation, symptothermal, postovu lation methods), 
declaration of abst inence for the duration of thestudy , and wi thdrawal  are not 
acceptable methods of contraception
Otherwi se, women of childbearing potential part icipating in this study  must agree 
to use 1highly effect ive method ( <1% fai lure rate) of contraception or a 
combinat ion of 2 effect ive methods of contraception from the time of signing the 
inform ed consent form  (ICF)to12 weeks fo llowing dosing wi th the 
investigat ional product [IP] )
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 21
LY3074828oEither 1highly effect ive method of contraception (such as combinat ion 
oral contraceptives, implanted con tracepti ves, an intrauterine device , or 
vaginal ring ) or a combinat ion of 2 effect ive methods of contraception 
(such as male or female condoms with spermicide, diaphragms with 
spermicide, or cervical sponges) will be used.  The subject may choose to 
use a doubl e-barrier method of contraception.  Barrier protection methods 
without concomi tant use of a spermicide are not reliable or acceptable 
method s.  Thus, each barrier m ethod m ust include use of a spermicide.  It 
shoul d be noted that the use of male and female condo ms as a 
doubl e-barrier method i s not considered acceptable due to the high failure 
rate when these methods are combined
Women not of childbearing pote ntial may partici pate and incl ude those who are
oinfertile due to surgical sterilizat ion (hysterectomy , bilateral 
oophorectomy , tubal  ligat ion, or bilateral  salpingectomy ) or congeni tal 
anomaly such as Müllerian agenesis; or
opostmenopausal , defined as 1 of the f ollowing :
A wo man at l east 50 years of age with an intact uterus, not on 
horm one replacement therapy , who has had either:
cessat ion ofmenses for at least 1 y ear; or
at least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one level >40 m IU/mL at 
screening ;or 
A wo man at least 55 years of age ,not on hormone replacement 
therapy , who has had at l east 6 m onths of spontaneous 
amenorrhea; or
A wo man at l east 55 years of age with a diagnosi s of menopause 
prior to starting hormone replacement therapy
[2] are between 18 and75 years of age at the time of screening
[3] have a body  mass index (BMI) of 18.0 to 32.0 kg/m 2, inclusive
[4] have clinical laboratory  test resul ts wi thin norm al reference ranges for the 
study site, or resul ts wi th acceptable deviat ions that are judged to be not 
clinically significant by  the investi gator
[5]have venous access sufficient to allow for blood samplin g as per the protocol
[6] agree not to donate blood or plasma unt il after the end of their part icipation in 
the study
[7]are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[8]areable and willing to give signed informed consent
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 22
LY30748286.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or Day  -1:
[9]are si te staff directly affiliated wi th this study  and their immediate families.  
Immediate family is defined as a spouse, bio logical or legal  guardian, child, or 
sibling
[10]are Lilly emplo yees or are emplo yees of a third -party  organi zation involved inthe 
study  
[11]are currently enrolled in a clinical study  involving an IP or any other type of 
medical research judged not to be scient ifically or medically co mpat ible with 
this study
[12]have participated in a clinical trial involving an IP within 30 days or 
5half-lives (whichever is lo nger) prior to screening.  If the clinical trial 
involved treatment with bio logic agents (such as monoclonal ant ibodies, 
including marketed drugs), at least 3 months or 5 half -lives (whichever is 
longer) should have elapsed prior to Day  1
[13]have previously completed or withdrawn fro m this study  or any  other study  
investigat ingmirikizumab , and have previously  received the IP
[14]have ever received ant i-IL-12p40 ant ibodies ( eg, ustekinumab [S telara ®]) or 
anti-IL-23p19 ant ibodies ( eg, risankizumab [BI -655066], brazikumab 
[MEDI2070], guselkumab [CNTO 1959], or tildrakizumab [MK -3222]) for 
any indicat ion, including invest igational use
[15]have known allergies to mirikizumab , related compounds, or any  com ponents 
of the form ulation, or hi story  of significant atopy
[16]have self -perceived dullness or loss of sensation ineither arm or thi gh or on 
either side of the abdo men
[17]have an abnormalit y in the 12 -lead ECG that, in the opinion o f the 
investigator, increases the risks associated with participat ing in the study
[18]have an abnormal blood pressure , pulse rate, or temperature as determined to 
be clinically  significant by the invest igator
[19]have a history  or presence of cardiovascular, res piratory , hepat ic, renal, 
gastrointestinal, endocrine, hematological, or neurological disorders capable 
of significant ly altering the absorption, metabolism, or eliminat ion of drugs; 
of const ituting a risk when taking the IP; or of interfering with the 
interpretati on of  data
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 23
LY3074828[20]Infections:
[20a] have had a serious infect ion (eg, pneumonia, cellulit is, sepsis) ;have been 
hospi talized or have received IV antibiotics for an infect ion within 
12weeks prior to Day  1; have had a serious bone or join tinfect ion within 
24 weeks prior to Day  1 or have ever had an infectio n of an artificial jo int; 
or are immunocompro mised to an extent that participat ion in the study  
woul d pos ean unacceptable risk to the subject as determined by the 
investigator
[20b] hav e or have had an infect ion typical of an immunocompromised host 
and/or that occurs with increased incidence in an immunocompromised 
host (including, but not limited to, Pneumocystis jiroveci ipneumo nia, 
histopl asmosis, or cocci dioidomycosis) or have a know n 
immunodeficiency
[20c] have or have had a herpes zoster infect ion or any  other clinically apparent 
varicella -zoster vi rus infect ion within 12 weeks of Day  1
[20d] have had any  other active or recent infection within 4 weeks of Day  1 
that, in the opinio n of the invest igator, would pose an unacceptable risk to 
the subject if participating in the study; these subjects may be re -screened 
(once) ≥4weeks after documented resolution of symptoms
[21]have known or ongoing psychiatric disorders deemed clinically significant by  
the invest igator
[22]regul arly use known drugs of abuse and/or show posit ive findings on 
drug screening
[23]show positive HIV ant ibodies
[24]show posit ive hepat itis C ant ibody
[25]show posit ive hepat itis B surface antigen or hepatitis B core antibody
[26]are wom en who are lactating
[27]intend or are likely  to use over -the-counter or prescript ion medication for pain
or inflammation wit hin 7 days prior to dose administration. Subjects on stable
doses of other medicat ions (eg, statins and ant ihypertensives) may be eligible
for enrolment following discussio n with the sponsor (Section 7.7)
[28]have donated blood or plasma of more than 500 mL wi thin 1 m onth prior to 
screening
[29]have an average weekly  alcohol  intake that exceeds 21 units per week (males) 
and 14 units per week (females), have a posit ive test for ethano l, or are 
unwilling to abide by the alcohol restrict ions described in Sect ion 6.3.2 of 
3units per day  (males) or 2units per day  (females) (1 uni t = 12 oz or 360 mL 
of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of dist illed spirits)
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 24
LY3074828[30]have a tobacco consumpt ion of more than 10 cigarettes per day  (or 
equivalent), or who are unwilling to abide by the CRU smoking guidelines 
described in Section 6.3.2
[31]show evidence of active or latent TB, as documented through medical history , 
examinat ion, and TB testing ( positive[not indeterminate] 
Quant iFERON ®-TB Gol d test ; if a repeat test is also indeterminate ,the 
subject will not be eligible ); or have had househo ld contact with a person with 
active TB, unless appropriate and documented prophylaxis treatment has been 
given.  Subjects with any history  of active TB are excluded fro m the study , 
regardl ess of previous or current TB treatments
[32]have received live va ccine(s), incl uding attenuated live vaccines and those 
administered intranasally, wit hin 8 weeks of screening, or intend to during the 
study (non-live or inact ivated vaccinat ions are not allowed 2 weeks pri or to ,
or 2 weeks after mirikizumab dosing, and th en they  must be given at an 
inject ion site remote from mirikizumab administratio n)
[33]have been treated with oral steroids wit hin 1 month of screening, or intend to 
during the study  (mild topi cal steroi d creams/ointments are permitted , with the 
exception of the injection day as specified in Sect ion 7.7)
[34]have significant allergies to humanized monoclonal antibodies
[35]have clinica lly significant m ultiple or severe drug allergies, or intolerance 
totopical corti costeroi ds, or severe posttreatment hypersensit ivity 
reacti ons(including, but not limited to, ery thema mul tiforme major, 
linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or 
exfoliative dermat itis)
[36]have had lympho ma, leukemia, or any  malignancy  within the past 5 years ,
except for basal cell or squamous epithelial carcinomas of the skin that have 
been resected wi th no evidence of metastatic disease for 3 years
[37]have had breast cancer within the past 10 y ears
[38]have any condit ion that coul d affect pain percept ion from an inject ion
[39]have excessive tattoos over eitherarm, eitherarm, either thigh, or either side 
of theabdo menthat woul d interfere wi th injecti on-site assessments
[40]in the opinio n of the invest igator, are unsuitable for inclusion in the study
6.2.1. Rationale for Exclusion o f Certain Study Candidates
Exclusio n criteria [9] and [ 10] prevent conflict of interest in study subject s.  Exclusion 
criteria [11]through [ 39] exclude items including, but not limited to medical condi tions, 
medicat ion intolerance, and concomitant medicat ion use that may confound the assessment 
ofstudy  endpoints .
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 25
LY30748286.3. Lifestyle and/or Dietary Requirements
Throughout the study , subjects m ay undergo m edical  assessments and review of compliance with 
requi rements before continuing in the study .  Female s ubjects will also be required to adhere to 
contraceptive requirements, as outlined in the inclusion criteria (Section 6.1).
6.3.1. Meals and Dietary Restrictions
Subjects will receive a light breakfast on the morning of Day  1 but are required to fast (water is 
permitted) from 1 hour prior to dosing unt il 1-hour postdose.  Standard meals will be provided 
atall other times while subjects are resident at the CRU, per the CRU’s policy.
6.3.2. Caffeine, Alcohol, and Tobacco
Subjects will not be allowed to consume caffeinated products during study  visit s and while 
resident at the CRU , but otherwi sesubjects will be allowed to maintain their regular caffeine 
consumption.
Alcoho l consumpt ion is not permitted while subjects are resident at the CRU and for 24hours 
prior to each study visit .  Alcohol  intake during outpatient periods should not exceed 3 units per 
day for males or 2units per day for females.   In addit ion, subjects must abide by the CRU 
smoking restricti ons during study  visit s and while resident atthe CRU.
6.3.3. Activity
Subjects will be advised to maintain their regular levels o f physical act ivity/exercise; however, 
they shoul d not undertake vigor ous or prol onged exercise within 48 hours prior to any visit in
which laboratory  safet y tests will occur (Day  -1, Day  15, Day  29,and Day 85).  While certain 
study  procedures are in progress at the site, subjects may be required to remain recumbent or 
sitting.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
re-screened , except as described in exclusion criterio n Section 6.2[20d].
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 26
LY30748287.Treatment
7.1. Treatment Administ ered
One 200-mg dose of IP will consist of 21-mLSC inject ionsusing 2 PFS of 100mg 
mirikizumab into the arms, thighs, or abdomen , according to the randomizat ion schedule .  
Subjects rando mized to a group with the arm or thigh as the inject ion area will have 
1.the first inject ionadministered to the leftlimb, and 
2.the second inject ion administered to the corresponding (contra -lateral) right limb.   
Subjects rando mized to t he group with the abdomen as the inject ion area will have 
1.the first inject ionadministered to the lower l eft quadrant, and
2.the second inject ion administered to the lower ri ght quadrant of the abdo men.  
The second injection should be administered 2 0(±2) minutes after the first inject ion.
This study  will co mpare single doses of 2 formulations:
200mg of Mirikizumab Reference Formulat ion(100mg/mL), 2×1-mL PFS
(administered in co mpleted and ongoing clinical studi es [see Secti on3.2])
200mg of Mirikizumab Test Form ulation (100mg/mL), 2×1-mL PFS
Trained site staff will administer all  doses.  Prior to the PFS inject ions, the invest igator or 
designee will clean the subject’s skin.  The injection swill be administered according to t he 
instructi ons provi ded by  thesponsor.
The invest igator or designee is responsible for
explaining the correct use of the IPto the site staff
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion, and
returning all unused medication sto Lilly  or its designee at the end of the study
Note : In some cases, site may destroy  the m aterial if, d uring the invest igational-site select ion, 
the evaluator has verified and documented that the site has appropriate facilit ies and written 
procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Mirikizumab will be supplied by the sponsor or its designee in accordance with current good 
manufacturing practice , labeled according to the country ’s regul atory  requi rements, and supplied 
with lot numbers, expiry  dates, and certificates of analysis, as applicable.
Each 1-mL syringe of mirikizumab (100mg/mL) is designed to deliver 100mg of mirikizumab .  
The fo llowing products will be supplied by  Lilly ,with study -specific l abels, for use in the study :
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 27
LY3074828Mirikizumab Reference Formulat ion (solut ion for inject ion) in 1-mL single -dose, 
pre-filled, disposable manual syringes
Mirikizumab Test Form ulation (so lution for inject ion) in 1-mL single -dose, pre -filled, 
disposable manual sy ringes
7.1.2. Medical Device
The invest igator or designee will ensure that the instructions have been fo llowed properly ,
maintaining accura te records of study  devices, di spensing, and collection.  The used or unused 
PFS m ay be destroyed by a qualified vendor.  However, a used PFS that is associated with a 
product complaint will need to be returned to Lilly.
7.2. Method of Treatment Assignment
Subjects will be randomly assigned to 1 of 2 possible treatm ents and 1 of 3 possible injection 
sites(arm s, thighs, or abdom en) using a co mputer -generated allocat ion code (Section 5.1).
7.2.1. Selection and Timing of Doses
Each subject will be administered 2 inject ions approximately 20 minutes apart to complete the 
single dose.  The actual time of all inject ions will be recorded in the subjec t’s el ectroni c case 
report form (eCRF).
7.3. Blinding
Blinding will be in place for subjects and for site staff conduct ing any inject ion-site assessments.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent assi gnment i s warranted for m edical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.  If the 
investigator decides that unblinding is warranted, it is t he responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dose Modification
Dose m odificat ion is not permitted in this study .
7.4.1. Special Treatment Considerations
All biological agents carry  the risk of systemic allergic/hypersensit ivity reacti ons.  Clinical  
manifestations of these reactions may include, but are not limit ed to ,rash, pruritus (itching), 
urticaria (hives), angioedema ( swelling of the lips and/or tongue), and anaphylact ic react ion.  
Sometimes these react ions can be life -threatening.  Proteins may  also cause redness, itching, 
swelling, or pain locally at the inject ion site.  Therefore, all subjec ts shoul d be 
closely  monitored f or signs or symptom s that could result from such react ions
educated on the signs or symptoms of these ty pes of  reacti ons, and 
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 28
LY3074828instructed to contact the study  site immediately if they experience any of thesesymptom s 
after discharge from the CRU.  
If a subject experiences an acute allergic/hypersensit ivity reacti on after an inject ion of IP, he or 
she should be managed appropriately and receive relevant supportive care.  The event should be 
recorded as an AE and a hypersensi tivity cytokine panel (Appendix 6 ) shoul dbe co llected .
7.5. Preparation/Handling/Storage/Accountability
Invest igational product swill be stored under refrigerated conditions at 2°C to 8°C (36°F to 46°F) 
in its original  carton to protect from light.  Invest igational product sshould not be frozen or 
shaken.
Site will be required to monitor the temperature of on -site IP storage condit ions.  The 
investigat or or desi gnee m ust confi rm that appropriate temperature condit ions have been 
maintained, as communicated by the sponsor, during transit for all IP sreceived and must confirm 
that any discrepancies are reported and resolved before use of the IPs.
Unblinded site staff will be responsible for handling and administering IP. Unblinded site staff
are al so responsible for ensuring thatsubjects remain blinded to treatment (ie, subjects must not 
see the sy ringe before, during ,or after IPadministration).   Blinde d assessors of any injection -site 
assessments and bleeding will not have access to the IP.
Only subjects enrolled in the study  may receive IP sor study  materials, and only  authori zed si te 
staff may supply or administer IPs.  All IP sshoul d be stored in an environmentally controlled 
and mo nitored (m anual  or autom ated) area in accordance wit h the l abeled storage condit ions 
with access limited to the invest igator and authorized site staff.
The invest igator is responsible for IPaccounta bility, reconciliat ion, and record maintenance 
(such as receipt, reconciliat ion, and final disposit ion records).
7.6. Treatment Compliance
The IP swill be administered at the clinical site, and documentation of treatment administration 
will occur at the site.
7.7. Concomitant Therapy
Subjects on stable conco mitant m edicat ion at the time of study  entry  shoul d cont inue their
regul ar, unchanged dose throughout the study . Permitted concomitant medicat ions, at the
discreti on of  the invest igator, include hormonal contraceptives, hormone replacement therapy ,
and thy roid repl acement. In addition, occasional acetaminophen is acceptable at the discretion o f
the invest igator. However, acetaminophen should not be administered on the dosing day wit hin
4 hours pri or to t he first inject ion and unt il at least 4 hours after the second inject ion. No m ore 
than 3 g of acetaminophen will be permitted in any 24 -hour period. Inclusio n of subjects on any  
other concomitant medicat ion (eg, statins and ant i-hypertensives) is contingent upon approval
following consultation wit h the sponsor.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 29
LY3074828Subjects will be restricted fro m applying any  creams or l otions on the arm, thigh, or abdominal
skin wit hin 24 hours prior to andafter the injection and subjects should not receive any 
additional SC inject ions at the site of mirikizumab administration for the duration of the study .
If the need for any  addi tional concomi tant m edicatio n arises, inclusion or continuat ion of the
participant may be at the discret ion of the investigator after cons ultation wi th a Lilly clinical
pharmaco logist (CP) or clinical research physician (CRP). Any medication used during the
study  must be docum ented.
7.8. Treatment after the End of the Study
This sect ion is not applicable for this study.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 30
LY30748288.Discontinuation Criteria
Subjects discont inuing fro m the study  prematurely for any  reason shoul d com plete AE and other 
Day 85/early  discontinuati onprocedures per Section 2of this protocol .
8.1. Discontinuation from Study Treatment
Not applicable in this single -dose study .
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a subject who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP/CRP and the invest igator to 
determine if the subject may cont inue in the study .  If both agree i t is medically appropriate to 
continu e, the invest igator must obtain documented approval fro m the Lilly CP/CRP to allow the 
inadvertent ly enro lled subject to continue in the study .  If the subject received IP, he or she will 
continue to be monitored for safet y and tol erabilit y for the planned durati on of  the study .
8.2. Discontinuation from the Study
Subjects will be discont inued under the following ci rcumstances:
Enrollment in any other clinical study  involving an IP or enrollment in any other type of 
medical research judged not to be scient ifically or medically co mpat ible with this study 
prior to receiving IP in this study .  If the subject received IP, he or she will cont inue to be 
monitored for safet y and tol erabili ty for the planned duration of the study .
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical practice(GCP) .
Investigator decision
othe invest igator decides that the subject should be discontinued fro m the study
Subject decision
othe subject, or legal representative, requests to be withdrawn from the study
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site staff are expected to m ake diligent 
attem pts to contact subjects who fail to return for a sch eduled visit or were otherwise unable to 
be followed up by the site.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 31
LY30748289.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that will be performed for this study.
Appendix 5 provi des a summary  of the m aximum  number and vol ume of invasive samples, for 
all sampling, during the study .
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test resul ts.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards .
9.1. Efficacy Assessments
This sect ion is no t applicable for this study .
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to t he subject .
The invest igator is responsible for the appropriate medical care of subjects during the study .
Invest igators must document their review of each laboratory  safety  repo rt.
The invest igator remains responsible for fo llowing, through an appropriate healt h care option, 
AEs that are serious or otherwise medically important, considered related to the IP or the study , 
or that caused the s ubject to discontinue the IP before complet ing the study .  The subject should 
be followed up until the event resolves, stabilizes with appropriate diagnostic evaluat ion, or i s 
reasonably  explained.  The frequency  of follow-up evaluat ions of the AE is left to the discret ion 
of the invest igator .
The invest igator will record all relevant AE and SAE informat ion in the eCRF.  After the 
inform ed consent form  is signed, site staff will record, vi a eCRF, the occurrence and nature of 
each subject’s preexist ing condit ions.  Addit ionally , site staff will record any  change in the 
condi tion(s) and the occurrence and nature of any AEs. 
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , study  device, or a study procedure, taking into account the 
disease, co ncomitant treatm ent,or pathologies .
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the IP, study device and/or study procedure ,and the AE .
Planned surgeries should not be reported as AEs ,unless the underlying medical condit ion has 
worsened during the course of the study .
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 32
LY3074828Prospective co llection of ISRs at predefined time points is included as part of this protocol.  As 
such, any  identified ISRs will n ot be collected as AEs but will instead be recorded using the 
predefined ISR collect ion tool s. 
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1of the f ollowing:
death
initial or prolonged inpatient hospitalizat ion
a life -threatening experience ( ie, immediate ri sk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life threatening or result in death 
or hospitalization but m ay jeopardi zethe subject or may requi re interventi on to prevent 1
of the other outcomes listed in the definit ion above
Site staff must alert the Lilly CRP/CP, or its designee, of any  SAE as soon as pract ically 
possible .
Addit ionally , site staff must al ert Lilly Global Patient Safet y,or its designee ,of any SAE wi thin 
24 hours of invest igator awareness of the event via a sponsor -approved method.  If aler ts are 
issued via telephone, they  are to be immediately fo llowed up with official  notificat ion on study -
specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE informat ion 
and all fo llow-up SAE informat ion.
Although all AEs are recorded in the eCRF after signing informed consent, SAE reporting to the 
sponsor begins after the subject has signed informed consent and has received IP.  However, if 
an SAE occurs after signing informed consent, b ut pri or to receiving IP, AND is considered 
Reasonably Possibly Related to a study  procedure then it MUST be reported .
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinu ed from and/or com pleted the study  (the subject summary eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus .
9.2.1.1. Adverse Device Effects
Any AE believed to have a reasonable possibilit y of being related to or associated withan issue 
with the PFS, such as a malfunct ion or a deficiency, is considered an adverse device event.  
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 33
LY3074828These events must be clearly indicated as such in the eCRF and reported to the sponsor.  A 
product complaint shoul d also be reported.
For the purpose sof this protocol , “unantici pated” seri ous adverse device effect means any SAE 
alleged to have a reasonable possibilit y ofbeingassoci ated with or rel ated to the device, which 
was not previously  defined as ant icipated in stu dy docum ents, such as the device IB or 
Instructi ons for Use.  The SAE relatedness must be clearly indicated as such in the eCRF, and 
reported to the sponsor within 24 hours of site knowledge o f the event.  A product complaint
shoul d also be reported.
9.2.1.2. Adver seEvents of Special Interest
The fo llowing AEs of special interest will be used to determine the safet y and tol erabilit y of 
mirikizumab formulationsadministered through PFS in this clinical study .
Adverse events of special interest for mirikizumab are
Infection
systemic allergic/hypersensit ivityreact ions
If infections or allergic/hypersensit ivity react ions are reported, sitestaffwill provide details on 
these events as instructed on the eCRF.  A PK , immun ogenici ty, and hypersensi tivity cytokine 
panel ( Appendix 6 )will be collected when possible for any  subject who experi ences an AE of 
systemic allergic/hypersensit ivity react ion during the study .
9.2.1.3. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure.  Lilly  has procedures that 
will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guidances .
9.2.2. Complaint Handling
Lilly co llects product complaints on IPsand drug delivery  systems used in clinical trials to 
ensure the safet y of study  subjects , monitor quali ty, and to facilitate process and product 
improvements .
Subjects should be instructed to contact the invest igator as soon as possible if they have a 
complaint or probl em wi th the IP or dru g delivery system so that the si tuation can be assessed .
The invest igator or designee is responsible for handling the fo llowing aspects of the product 
complaint process in acco rdance with the instructions provided for this study :
recording a complete descript ion of the product complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed Product Complaint Form w ithin 24 hours to Lilly or its designee
If the invest igator is asked to return the product for invest igation, he or she will return a copy of 
the product complaint form with the product.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 34
LY30748289.3. Treatment of Overdose
For the purposes of this study , an overdose of mirikizumab is considered any dose higher than 
the 200-mgdose assigned through randomizat ion.  Sy ringes used in this study can deliver a 
1-mL volume o f mirikizumab and each dose will require 2 sy ringes.
There i s no specific antidote for mirikizumab .  In the event of an overdose, the subject should 
receive appropriate supportive care and any AEs should be documented.
Refer to the mirikizumab IB for further details.
9.4. Safety
9.4.1. Laboratory Tests
For each subject, laboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Secti on2).
9.4.2. Vital Signs
For each subject, vital sign measurements should be conducted according to the Schedule o f 
Activities (Section 2).  Addit ional vital signs m ay be measured during the study , ifwarranted.
Blood pressure and pulse rate should be measured after the subject has been sitt ing for at least 
5minutes .
If the subject feels unable to stand, supine vital signs only  will be recorded.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.
9.4.3. Electrocardiograms
For each subject , a single 12 -lead ECG shoul d be collected according to the Schedule of 
Activities (Secti on 2).
Electrocardiograms must be recorded before collecting any blood samples.   Subjects must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
during ECG collect ion.  Electrocardi ograms m ay be obtained at addit ional times,when deemed 
clinically necessary .  All ECGs recorded should be stored at the study site.
Electrocardiograms will be interpreted by  a qualified invest igator (the physician or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically re levant findings 
beident ified.
9.4.4. Temperature
Body  temperature will be assessed at the times indicated in the Schedule of Activit ies (Secti on2).
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 36
LY3074828 
 
9.4.6. Safety Monitoring
The Lilly -assigned CPor CRP /scientist will monit or safet y data throughout the course of the 
study .  Lilly will review SAEs wit hin time frames mandated by company procedures.  The Lilly 
CPor CRP will periodically  review trends in safety  data, l aboratory  analy tes, and AEs.
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
9.4.6.1. Hepatic Safety
If a study  subject experiences elevated alanine aminotransferase (ALT )≥3upper limit of 
norm al (ULN ), alkaline phosphatase ( ALP )≥2ULN , or el evated total  bilirubin (TBL) 
≥2ULN, liver tests ( Appendix 4 ) shoul d be repeated wi thin 3 to5days including ALT, 
aspartate aminotransferase , ALP, TBL, direct bilirubin , gamma -glutamyl transferase,
andcreat inine kinase to confirm the abnormalit y and to determine if it is increasing or 
decreasing.  If the abnormalit y persists or worsens, clinical and laboratory  monitoring shoul d be 
initiated by  the invest igator based on consultation with the Lilly CPor CRP .  Moni toring shoul d 
continue until levels normalize and/or are return ingto approximate baseline levels .
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5ULN on 2or more consecut ive blood tests
elevation ofserum  TBL to ≥2ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALP to ≥2ULN on 2or more consecut ive blood tests
subject discontinued from treatment due to a hepatic event or abnormalit y of 
liver tests
hepatic event considered to be a nSAE
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 2), venous blood samples 
of approximately  3mL each will be co llected to determine the serum concentrations of
mirikizumab .  A maximum of 3 samples may be collected at addit ional time po ints during the 
study  if warranted and agreed upon between both the investigator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.  The actual date 
and time (24- hour cl ock time) of each sampling will be recorded.
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 37
LY3074828 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 38
LY3074828 
 
 
 
 
 
 
  
 
9.8. Biomarker s
This sect ion is not applicable for this study .
9.9. Health Economics
Thissection is not applicable forthis study .
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 39
LY307482810. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Up to 60subjects may be enro lled to ensure that 48subjects (24subjects per treatm ent 
formulation with approximately  8subjects per treatm ent formulation and injection site[arm, 
thigh, or abdom en])complete the study .
Based on previous trials,it isexpect ed that the coefficient of variat ion for area under the 
concentration versus t ime curve ( AUC )and maximum observed drug concentration (C max)tobe
approximately  40% . Asample size of 48completed subjects (24 subjects per treatment
formulation) will  provide >90% probabilit y that the limits of the 90% confidence interval (CI) 
for the rati o of geom etric mean swill be within 24% of the estimate.
Subjec ts who are randomized but not administered treatment m ay be repl aced to ensure that 
48subjects (24pertreatment formulation) com plete the study .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study .
10.2.2. Study Participant Characteristics
The subjects’ age, sex, weight, height, BMI, race, and other demographic characterist ics will be 
recorded and summarized using descript ive statist ics.
10.3. Statistical Anal yses
Statistical anal ysis o f this study  will be the responsibilit y of Eli Lilly and Company (Lilly) or 
itsdesignee.
Pharmacokinet ic analyses will be conducted on data fro m all subjects who receive mirikizumab
and have evaluable PK data.
Safety analyses will be conducted for a ll enro lled subjects ,regardless of whether they  com plete 
all protocol requirements.
.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PK analy sis purposes to 
avoid issues with post hoc analyses and inco mplete di sclosures of analyses.
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All IP and protocol procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summarized using descript ive methodol ogy.
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 41
LY3074828The t maxwill be analyzed using a Wilcoxon rank sum test.  Es timates of the median difference 
based on the observed medians, 90% C Is,and p -values from the Wilcoxon rank sum test will 
becalculated.
 
 
 
 
 
 
 
10.3.4. Data Review during the Study
Review of the PK and safet y data m ay be conducted during the conduct of this study  to inform  
internal  Chemistry , Manufacturing, and Control processes with regard to the test mirikizumab 
formulationdevel opment.
10.3.5. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the Lilly CP/CRP/investigator or designee will consult with the appropriate medical 
director or desi gnee to determine if it is necessary  to am end the protocol .
CCI
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 42
LY307482811. References
Cornelissen F, Asmawidjaja PS, Mus AM, Corneth O, Kikly K, Lubberts E. IL -23 dependent and 
independent stages of experimental arthrit is: no clinical effect of therapeutic IL -23p19 
inhibit ion in co llagen -induced arthrit is. PLoS One . 2013;8(2):e57553.
Laursen T, Hansen B, Fisker S. Pain perception aft er subcutaneous inject ions of m edia 
containing diff erent buffers. Basic Clin Pharmacol Toxicol . 2006;98(2):218 -221.
Ruutu M, Thomas G, Steck R, Degli -Espost i MA, Zinkernagel MS, Alexander K, Velasco J, 
Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pettit AR, 
Brown MA, McGuckin MA, Thomas R. β-glucan tri ggers spondylarthrit is and Crohn ’s 
disease -like ileit is in SKG mice. Arthritis Rheum . 2012;64(7):2211 -2222.
Williamson A, Hoggart B. Pain: a review o f three commo nly used pain rat ing scales. J Clin 
Nurs . 2005;14(7):798 -804.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 43
LY307482812. Appendices
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 44
LY3074828Appendix 1. Abbreviations and Definitions
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 45
LY3074828Term Definition
ADA antidrug antibod y
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not relate d to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from time zero to infinity
AUC(0 -tlast) areaunder the concentration versus time curve from time zero to time t, where t is last the 
time point with a measurable concentration
blinding A procedure in which 1or more parties to the study are kept unaw are of the treatment 
assignment s.  Unless otherwi se specified, blinding will remain in effect until final database 
lock.
A single -blind study is one in which the investigator and/or site staff are aware of the 
treatment , but the subject is not, or vice versa ;or when the sponsor is aware of the 
treatment ,but the investigator ,site staff,and the subject are not.  A double -blind study  is 
one in which neither the subject nor any of the investigator or sponsor staff who are 
involved in the treatment or clinical evaluation of the subjects are aware of the treatment 
received .
BMI body mass index
CI confidence interval
Cmax maximum observed drug concentration 
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effecti veness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be hel d to be re -tested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP clinical pharmacologist
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 46
LY3074828CRP clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician ,or other medical officer.
CRU clinical research unit
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.   Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
GCP good clinical practice
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmoni sation
IL interleukin
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate.  Informed consent is documented by means of a 
written, signed ,and dated informed co nsent form.  
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigator A person responsible for the conduct of the c linical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IP investigational product:  A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical study, including products already on the market 
when used or assembled (formulated or packaged) in a way different from the authorized 
form, or marketed products used for an un authorized indication, or marketed products used 
to gain further information about the authorized form.
ISR injection -site reaction
IV intravenous
legal 
representativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical study.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 47
LY3074828PFS pre-filled syringe
PK pharmacokinetic (s)
randomize The process of assigning subjects to an experimental group on a random basis
SAE serious adverse event
SC subcutaneous ; subcutaneously
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
SUSAR suspected unexpected serious adverse reaction
t1/2 half-life associated with the terminal rate constant in noncompartmental analysis
TB tuberculosis
TBL total bilirubin
TE-ADA treatment -emergent antidrug antibod y
TE-ADA+ treatment -emergent antidrug antibody positive
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have to have a causal relationship wi th this 
treatment 
tmax time of maximum observed drug concentration
UC ulcerative colitis
ULN upper limit of normal
VAS visual analog scale
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 48
LY3074828Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rous
Leukocytes (WBC) Glucose (random)
BUN
Cell morphology Uric acid
Absolute counts of: Total cholesterol
Neutrophils Total protein
Lymphocy tes Albumin
Monocytes Total bilirubin
Eosinophils Direct bilirubin
Basophils ALP
Platelets AST
ALT
Urinalysis Creatinine
Specific gravity
pH
Protein Other Tests
Glucose Ethanol testing b,c
Ketones Urine drug screen b,c
Bilirubin Pregnancy test (females only, if applicable)
Urobilinogen FSHa
Blood QuantiFERON ®-TB Gold a
Nitrite
Microscopy (if dipstick abnormal )
Serology
Hepatitis B surface antigen a
Hepatitis B core antibody a
Hepatitis C antibody a
HIVa
Abbreviations:  ALP = alkaline phosphatase; ALT = alanin e aminotransferase; AST =aspartate aminotransferase; 
BUN = blood urea nitrogen; FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ; 
RBC =red blood cell; TB = tuberculosis; WBC = white blood cell.
aPerformed at screening only .
bPerformed at screening and Day -1 only.
cUrine drug screen and ethanol level may be repeated at other times indicated in the Schedule of Activities
(Section 2).
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 49
LY3074828Appendix 3. Study  Governance, Regulatory ,and 
Ethical Considerations
Informed Consent
The invest igator is responsible for
ensuring that subject s understand the nature of the study ,the potenti al risks and benefi ts 
of parti cipat ing in the study , and that thei r parti cipati on is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaining the app ropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of IP.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the study .
providing a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Recruitment
Lilly or its desi gnee is responsible for the central recruit ment strategy  for subj ects.  Individual 
investigators may have addit ional local requirements or processes.  Study -specific recruit ment 
materi alsshoul d be approved by  Lilly.
Ethical Review
The invest igator or appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by  Internat ional Council for Harmoni sation (ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval o f the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the study site(s).  Lilly  or its representatives must approve the ICF before it is 
used at the study site(s).  All  ICFs must be com pliant wi th the ICH gui delin e on GCP .
The study  site’s ERB(s) shoul d be provi ded wi th the f ollowing:
the current IBandSummary of Product Characteristics and updates during the course of 
the study
ICF, and
relevant curri cula vi tae.
Regulatory Considerations
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 50
LY3074828This study  will be conduc ted in accordance wit hthe protocol and with
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council for International Organizations of 
Medical Sciences Internat ional Ethi cal Guidelines
applicable ICH GCP Guidelines , and
applicable laws and regulations .
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming tha t, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of 
thestudy .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and stat istician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
Provide instructi onal material to the study  site, as appropri ate.
Providetraining to instruct the invest igators and study coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRFs , and study  procedures .
Make peri odic visi ts to the study  site.
Be available for consultation and stay  in contact wit h the site staff through e mail, 
telephone, or fax .
Review and evaluate eCRF data and/or use standard computer edits to detect errors in 
data collection.
Conduct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 51
LY3074828The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original 
source documents.
Data Collection Tools/Source Data
An electronic data captur e system will be used in this study.  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have c ontrol s and requi rements in accordance wit h local 
data protecti on law.
The p urpose and use of subject personal informat ion collected will be provided in a written 
docum ent to the subject by the sponsor .
Study and Site Closure
Discontinuation of Study Site
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee ,the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuati on of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 52
LY3074828Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and 
may be required in fo llow-up wi th subjects in consultation with Lilly  or its design ated CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear Antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT Anti -smooth Muscle Antibody 
(or Anti-actin Antibody) a CPK
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by Lilly -designated or local laboratory.
bReflex/con firmation dependent on regulatory requirements and testing availability .
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 53
LY3074828Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling ( screening, clinical laboratory , PK, immunogenicit y, and bioanalyt ical assays ) 
during the study .
Protocol I6T-MC-AMBV Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening testsa 45 1 45
Clinical laboratory tests a 12 4 48
Pharmacokinetics 3 15b45
Immunogenicity 10 4 40
Pharmacogenetics 10 1 10
Total 188
Total for clinical purposes 190
aAdditional samples may be drawn if needed for safety purposes.
bIncludes additional 3 samples, if required .
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 54
LY3074828Appendix 6. Allergic/Hy persensitivity  Reaction Kit
Selected tests may be obtained in the event of anaphylaxis or generalized urticaria.
Hypersensitivity Tests a
Anti-mirikizumab antibodies (immunogenicity) Tryptase
Mirikizumab concentration (PK) N-methy lhistamine
Drug -specific IgE b
Basophil activation testb
Complements
Cytokine panel
Abbreviations:  Ig=immunoglobulin; PK = pharmacokinetic s.
aAssay edby Lilly -designated laboratory .
bBasophil activation test will be performed if a drug -specific IgE assay is unavailable.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 55
LY3074828Appendix 7. Protocol A mendment I6T-MC-AMBV (a) 
Summary  Relative Bioavailability  of a Mirikizumab Test 
Formulat ion Compared to the Reference Formulation in 
Healthy Subjects
Overview
Protocol  I6T-MC-AMBV , “Relative Bioavailabilit y of a Mi rikizumab Test Form ulation 
Com pared to the Reference Form ulation in Heat hy Subj ects”,has been amended.  The new 
protocol  is indicated by  Amendment ( a) and will be used to conduct the study  in place of any 
preceding versio n of the protocol.
The overall changes and rationale for the changes made to this proto col are as fo llows:
Expand edexclusio n criterion[10] to exclude employ ees of a nythird -party  organi zation 
to be invo lved in the study
The l anguage in e xclusio n criteria [23], [24], and [25] is modified to clarify  subjects wi th 
positive HIV ant ibodies, hep atitis C antibodies, hepatit is B surface antigen or hepatit is B 
core anti bodies will be excluded
Included timeframe for subjects who have had househo ldcontact wi th a person wi th 
active TB to be excluded from study
Throughout the protocol change shavebeen made to reflect the fact that the study  will be 
conducted at a single study  site. These changes arenotpresented in the revised section 
below.
I6T-MC-AMBV (a)Clinical Pharmacology Protocol Page 56
LY3074828Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
6.2 Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or Day  -1:
[9]are si te staff directly affiliated wi th this study  and their immediate families.  
Immediate family is defined as a spouse, bio logical or legal  guardian, child, or 
sibling
[10]are Lilly or Covance empl oyees or are em ployees of a thi rd-party  organi zation 
involved inthe study  
[23]show evidence of HIV infection and/or posit ive HIV ant ibodies
[24]show evidence of hepatit is C and/or positive hepat itis C ant ibody
[25]show evidence of hepatit is B and/or positive hepat itis B surface antigen or hepatit is 
B core antibody
9.4.5.1 Tuberculosis Testing
Subjects who have had househo ld contact with a person with active TB within 1 y ear of  
screening must be exclud ed
Leo Document ID = 9dc24504-fe1f-4a57-8b01-c4098bb8ebf9
Approver: 
Approval Date & Time: 17-Aug-2020 14:09:30 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 17-Aug-2020 15:49:23 GMT
Signature meaning: Approved
PPD
PPD